52w high/low | ₹54.45 / ₹25.2 |
P/E ratio | 34.88 |
Dividend | 0 |
ROE | 7.24 |
ROCE | 8.5 |
Face value | 10 |
Book value | ₹34.33Cr |
Market capital | ₹25.97Cr |
What is shareholding pattern? Who are shareholders?
What is a cash flow statement?
What is a balance sheet?
What is a profit and loss statement?
What are dividends?
What are bonuses?
Ishita Drugs & Industries was incorporated in Feb. '92 by Jagdish Agarwal. The company set up a project to manufacture bulk drugs at Sanand, in the Ahmedabad district of Gujarat with an installed capacity of 408 tpa. Commercial production commenced in Jan. '95. Recession in some international markets and intense dumping of the Chinese exporters of the bulk drugs originally planned in the product range, necessiated a review by the company of its production programme and product range. It decided to undertake production of fluoro-quinolones, the latest broad spectrum anti-bacterials. The company established an in-house R&D laboratory which has developed a highly improved process technology for norfloxacin.